Clinical trial NCT00108823: The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
Official title: A 24-week, Double Blind, Randomized Study to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Parameters Indicative of Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Obstructive Pulmonary Disease, COPD
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-04-20
Enrollment: 550
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.


Eligibility criteria: Main Inclusion Criteria:

* Written informed consent
* Patients with a history of chronic obstructive pulmonary disease for at least 12 months as defined by the GOLD (Global Initiative on Obstructive Lung Diseases) criteria (2003)
* Age ≥ 40 years
* FEV1/FVC ratio (post-bronchodilator) ≤ 70%
* FEV1 (post-bronchodilator) ≤ 65% of predicted
* FRC (post-bronchodilator) ≤ 120% of predicted
* Clinically stable COPD within 4 weeks prior to baseline visit (B0).
* Availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit (B0) or a willingness to have a chest x-ray performed at visit (B0).

Main Exclusion Criteria:

* COPD exacerbation indicated by a treatment with systemic glucocorticosteroids not stopped at least 4 weeks prior to the baseline visit (B0)
* Non smoker, current smoker or ex-smoker (smoking cessation at least one year ago) with a smoking history of \< 10 pack years
* Suffering from any concomitant disease that might interfere with study procedures or evaluation
* Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit (B0)
* Diagnosis of asthma and/or other relevant lung disease (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease \[e.g. fibrosis, silicosis, sarcoidosis\], and active tuberculosis)
* Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 2 months preceding the baseline visit (B0).
* Known alpha-1-antitrypsin deficiency
* Need for long term oxygen therapy defined as ≥ 15 hours/day
* Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator)
* Known infection with HIV, active hepatitis and/or liver insufficiency
* Diagnosis or history of cancer (other than basal cell carcinoma) or recurrence within 5 years prior to study start
* Clinically significant cardiopulmonary abnormalities (diagnosed clinically or by x-ray/ECG) that are not related to COPD and that require further evaluation
* Pregnancy, breast feeding, oocyte donation or oocyte implantation planned during the trial
* The female patient is of childbearing potential and is not using and is not willing to continue to use a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless she is surgically sterilized/hysterectomized or post-menopausal \> 1 year or any other criteria considered sufficiently reliable by the investigator in individual cases
* Participation in another study (use of investigational product) within 30 days preceding the baseline visit (B0) or re-entry of patients already enrolled in this trial
* Suspected inability or unwillingness to comply with study procedures
* Alcohol or drug abuse
* Inability to follow study procedures due to, for example, language problems or psychological disorders
* Use of prohibited drugs
* Suspected hypersensitivity to the study medication and/or contraindication to any ingredients of the study medication (roflumilast) or rescue medication

Primary outcomes:
measure: Lung function parameters indicative of hyperinflation in patients with COPD
Secondary outcomes:
measure: Mean change from randomization to endpoint in additional pre and post bronchodilator spirometric and lung volume parameters
measure: Measurement of quality of life parameters and dyspnea
Other outcomes:
Locations:
city: Cities in California
country: United States
facility: ALTANA Pharma
state: California
city: Cities in Colorado
country: United States
facility: ALTANA Pharma
state: Colorado
city: Cities in Florida
country: United States
facility: ALTANA Pharma
state: Florida
city: Cities in Missouri
country: United States
facility: ALTANA Pharma
state: Missouri
city: Cities in New Mexico
country: United States
facility: ALTANA Pharma
state: New Mexico
city: Cities in New York
country: United States
facility: ALTANA Pharma
state: New York
city: Cities in Oregeon
country: United States
facility: ALTANA Pharma
state: Oregon
city: Cities in South Carolina
country: United States
facility: ALTANA Pharma
state: South Carolina
city: Cities in Texas
country: United States
facility: ALTANA Pharma
state: Texas
city: Cities in Washington
country: United States
facility: ALTANA Pharma
state: Washington
city: Cities in Canada
country: Canada
facility: ALTANA Pharma
city: Cities in France
country: France
facility: ALTANA Pharma
city: Cities in Poland
country: Poland
facility: ALTANA Pharma
city: Cities in South Africa
country: South Africa
facility: ALTANA Pharma
city: Cities in Spain
country: Spain
facility: ALTANA Pharma
city: Cities in the United Kingdom
country: United Kingdom
facility: ALTANA Pharma
Study officials:
affiliation: AstraZeneca
name: AstraZeneca AstraZeneca
role: STUDY_DIRECTOR
References: